Literature DB >> 20590573

Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity.

A J Wheal1, S P H Alexander, M D Randall.   

Abstract

BACKGROUND AND
PURPOSE: The endocannabinoid-like molecule N-oleoylethanolamine (OEA) is found in the small intestine and regulates food intake and promotes weight loss. The principal aim of the present study was to evaluate the vascular effects of OEA. EXPERIMENTAL APPROACH: Perfused isolated mesenteric arterial beds were pre-contracted with methoxamine or high potassium buffers and concentration-response curves to OEA were constructed. Combinations of inhibitors to block nitric oxide production, sensory nerve activity, cyclooxygenase activity, potassium channels, chloride channels and gap junctions, and a cannabinoid CB(1) receptor antagonist, were used during these experiments. The effects of OEA on caffeine-induced contractions in calcium-free buffer were also assessed. Isolated thoracic aortic rings were used as a comparison. KEY
RESULTS: OEA caused concentration-dependent vasorelaxation in rat isolated mesenteric arterial beds and thoracic aortic rings, with a greater maximal response in mesenteric vessels. This relaxation was sensitive to inhibition of sensory nerve activity and endothelial removal in both preparations. The cyclooxygenase inhibitor indomethacin reversed the effects of capsaicin pre-treatment in perfused mesenteric arterial beds and indomethacin alone enhanced vasorelaxation to OEA. The OEA-induced vasorelaxation was inhibited by a CB(1) receptor antagonist only in aortic rings. In mesenteric arteries, OEA suppressed caffeine-induced contractions in calcium-free buffer. CONCLUSIONS AND IMPLICATIONS: The vasorelaxant effects of OEA are partly dependent on sensory nerve activity and a functional endothelium in the vasculature. In addition, vasorelaxation to OEA is enhanced following cyclooxygenase inhibition. OEA may also interfere with the release of intracellular calcium in arterial preparations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590573      PMCID: PMC2931569          DOI: 10.1111/j.1476-5381.2010.00770.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance.

Authors:  N Ueda; K Yamanaka; S Yamamoto
Journal:  J Biol Chem       Date:  2001-07-19       Impact factor: 5.157

Review 2.  EDHF: bringing the concepts together.

Authors:  Rudi Busse; Gillian Edwards; Michel Félétou; Ingrid Fleming; Paul M Vanhoutte; Arthur H Weston
Journal:  Trends Pharmacol Sci       Date:  2002-08       Impact factor: 14.819

3.  U46619, a thromboxane A2 agonist, inhibits KCa channel activity from pig coronary artery.

Authors:  F S Scornik; L Toro
Journal:  Am J Physiol       Date:  1992-03

4.  Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons.

Authors:  H H Hansen; S H Hansen; A Schousboe; H S Hansen
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

5.  Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.

Authors:  A Giuffrida; F Rodriguez de Fonseca; F Nava; P Loubet-Lescoulié; D Piomelli
Journal:  Eur J Pharmacol       Date:  2000-11-17       Impact factor: 4.432

6.  Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed.

Authors:  David Harris; Audrey I McCulloch; David A Kendall; Michael D Randall
Journal:  J Physiol       Date:  2002-03-15       Impact factor: 5.182

7.  Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

Authors:  R White; W S Ho; F E Bottrill; W R Ford; C R Hiley
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Activation of TRPV1 by the satiety factor oleoylethanolamide.

Authors:  Gerard P Ahern
Journal:  J Biol Chem       Date:  2003-05-21       Impact factor: 5.157

9.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha.

Authors:  Jin Fu; Silvana Gaetani; Fariba Oveisi; Jesse Lo Verme; Antonia Serrano; Fernando Rodríguez De Fonseca; Anja Rosengarth; Hartmut Luecke; Barbara Di Giacomo; Giorgio Tarzia; Daniele Piomelli
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

10.  Mechanisms of vasorelaxation to testosterone in the rat aorta.

Authors:  Patcharin Tep-areenan; David A Kendall; Michael D Randall
Journal:  Eur J Pharmacol       Date:  2003-03-28       Impact factor: 4.432

View more
  5 in total

Review 1.  Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Authors:  Virna Margarita Martín Giménez; Sandra Edith Noriega; Diego Enrique Kassuha; Lucía Beatriz Fuentes; Walter Manucha
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-16

2.  Hormone-sensitive lipase is localized at synapses and is necessary for normal memory functioning in mice.

Authors:  Cecilia Skoug; Cecilia Holm; João M N Duarte
Journal:  J Lipid Res       Date:  2022-03-15       Impact factor: 6.676

3.  Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries.

Authors:  Marta Baranowska-Kuczko; Hanna Kozłowska; Mirosław Kozłowski; Eberhard Schlicker; Monika Kloza; Arkadiusz Surażyński; Emilia Grzęda; Barbara Malinowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-02-28       Impact factor: 3.000

4.  Characterization of hypotensive and vasorelaxant effects of PHAR-DBH-Me a new cannabinoid receptor agonist.

Authors:  Oscar Alberto López-Canales; Natalia Pavón; Laura Matilde Ubaldo-Reyes; Marco Antonio Juárez-Oropeza; Patricia Victoria Torres-Durán; Ignacio Regla; María Cristina Paredes-Carbajal
Journal:  Korean J Physiol Pharmacol       Date:  2022-03-01       Impact factor: 2.016

Review 5.  Vascular targets for cannabinoids: animal and human studies.

Authors:  Christopher Stanley; Saoirse E O'Sullivan
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.